Department of Human Papillomavirus and оthers оncovirus Research

Diagnosis and treatment of cervical cancer (CC) is an important problem of women's reproductive health. More than 500,000 new cases of the disease are diagnosed in the world every year, of which over 50% are fatal. The human papillomavirus (HPV) in 1996 was officially recognized by WHO as an etiological factor in the development of cervical cancer. Knowledge of the mechanisms of cervical cancer development, from the moment of infection with HPV to the development of cervical cancer, takes an average of 5-10 years, which makes this oncological disease by far the most "controllable" and preventable. The costs of organizing, screening cervical cancer, treatment of precancerous conditions (cryotherapy, electrocoagulation or conization of the cervix) are many times less than the costs of treating advanced forms of invasive cervical cancer (volumetric surgeries, radiation and chemotherapy, long-term rehabilitation).

The success of cervical cancer screening depends on the following factors: the degree of knowledge of the epidemiology of the disease; from the presence of a single comprehensive screening program approved by the Ministry of Health; on the level of awareness of the population and the skills of personnel in the technique of taking, fixing a smear and filling out an accompanying document; from using the database to conduct analysis and determine the direction of further work. Of all the above factors, the main ones at the moment are informing the population and training the medical staff in the technique of material collection. The test characteristics depend on the quality of the cytological smear.

In this regard, the Research Institute of Virology is studying the effectiveness of using at the population level the primary methods of screening for cervical cancer - liquid cytology (Pap test) and HPV DNA testing, with further genotyping, of the Human Papilloma Virus (HPV). A research project jointly with KOFIH "Improvement of research and diagnosis of human papillomavirus (HPV) in the Republic of Uzbekistan" will contribute to the development of evidence-based recommendations for the use of the above primary screening methods to identify precancerous conditions and further strengthen the health of women in our Republic, as well as contribute to capacity building medical institutions in Uzbekistan.

Lokteva Lyubov Mikhaylovna

From May 5, 2023:

Head of the "Papillomavirus and Oncovirus" research department

LABOR ACTIVITY

2004-2011 - Student of Tashkent Pediatric medical Institute

2011-2014 - Master of the Tashkent Pediatric medical Institute

2013-2014 - Manager of "British pharma" limited liability company

2014-2016 - Infectious disease doctor of Kungirot District Medical Association

2016-2021 - Doctor of virology at the "Referens" laboratory of the Institute of Virology

2021-2023 - Master's student at Hiroshima University, Japan

2023 - h.v. - Head of the Research Department "Papillomavirus and Oncovirus" of the Virology research Institute of the Republican specialized epidemiology, microbiology, infectious and parasitic medical center